On June 11, 2020, Regeneron Pharmaceuticals initiated the first of its randomized, placebo-controlled clinical trials of REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19. Th e trials were conducted at multiple sites and consisted of four study populations—hospitalized COVID-19 patients, non- hospitalized symptomatic COVID-19 patients, …
Read More »
Medicosnext